1. Revolutionizing Treatment: The Promise of Cellular Therapy and Stem Cells for Sarcopenia at DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand
Cellular Therapy and Stem Cells for Sarcopenia represent a groundbreaking frontier in regenerative medicine, introducing novel cellular-based interventions for this debilitating age-related muscle-wasting disorder. Sarcopenia is characterized by progressive loss of skeletal muscle mass, strength, and function due to aging, hormonal decline, chronic inflammation, mitochondrial dysfunction, and reduced satellite cell activity. Traditional treatments—such as resistance training, nutritional supplementation, and pharmacological agents—offer only modest benefits in slowing muscle loss but fail to regenerate deteriorated muscle tissue or reverse the underlying cellular and molecular pathologies.
The integration of Cellular Therapy and Stem Cells for Sarcopenia is redefining the landscape of geriatric medicine by harnessing the regenerative and anti-inflammatory potential of stem cells, including mesenchymal stem cells (MSCs), satellite cells, and induced pluripotent stem cells (iPSCs). These cells possess the ability to differentiate into myogenic lineages, secrete trophic factors that rejuvenate aged muscle fibers, and modulate immune and oxidative stress responses within the muscular microenvironment.
Despite advancements in geriatrics and sports medicine, current therapeutic options for Sarcopenia remain limited in restoring muscle structure and contractile function. Pharmacologic interventions targeting myostatin, androgen pathways, or mitochondrial metabolism primarily slow degeneration but do not regenerate lost myofibers or restore neuromuscular connectivity. The persistent decline in muscle homeostasis leads to frailty, insulin resistance, metabolic dysfunction, and impaired mobility in the elderly—emphasizing an urgent need for regenerative strategies that go beyond symptomatic relief.
The convergence of Cellular Therapy and Stem Cells for Sarcopenia marks a paradigm shift in regenerative geriatrics. Imagine a future where age-related muscle loss can be reversed at the cellular level—where muscle fibers are rejuvenated, mitochondrial efficiency is restored, and mobility is regained. This emerging therapeutic avenue offers not only the promise of functional restoration but also the potential to extend healthspan, resilience, and independence in aging populations.
At DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand, our scientists and clinicians stand at the forefront of this revolutionary approach—pioneering evidence-based regenerative protocols that harness cellular rejuvenation and biological repair to combat the root causes of Sarcopenia [1-5].
2. Genetic Insights: Personalized DNA Testing for Sarcopenia Risk Assessment before Cellular Therapy and Stem Cell Treatment
Before initiating Cellular Therapy and Stem Cells for Sarcopenia, our team of regenerative medicine specialists and genetic researchers at DrStemCellsThailand provides Personalized DNA Testing to identify genetic predispositions contributing to muscle degeneration and metabolic decline. This genomic assessment focuses on variations in genes that regulate muscle mass maintenance, anabolic signaling, and mitochondrial function—providing patients with precise insights into their muscle health profile.
Key gene markers analyzed include:
- ACTN3 (Alpha-Actinin-3): Influences muscle fiber composition and contractile performance.
- MSTN (Myostatin): Regulates skeletal muscle growth; genetic mutations may predispose individuals to accelerated muscle loss or hypertrophic potential.
- IGF1 and IGF1R (Insulin-like Growth Factor Pathway): Involved in anabolic signaling crucial for muscle regeneration and protein synthesis.
- PPARGC1A (PGC-1α): Governs mitochondrial biogenesis and oxidative metabolism, impacting endurance and muscle quality.
- FOXO3 and SIRT1: Key regulators of longevity, muscle atrophy, and autophagy.
By integrating this genomic data, our team can design individualized pre-treatment optimization programs, including targeted nutrition, hormone modulation, and exercise regimens, ensuring that Cellular Therapy outcomes are maximized. This personalized, precision-based approach empowers patients to take proactive steps toward preserving and restoring muscle vitality while minimizing degenerative risk factors.
At DrStemCellsThailand, DNA-based risk profiling serves as the first step in a scientifically guided regenerative journey—enabling early detection, personalized prevention, and superior therapeutic response to Cellular Therapy and Stem Cells for Sarcopenia [1-5].
3. Understanding the Pathogenesis of Sarcopenia: A Detailed Overview
Sarcopenia arises from a complex interplay of cellular senescence, mitochondrial dysfunction, hormonal decline, and chronic inflammation that progressively erode muscle mass and function. Understanding these mechanisms at the molecular and cellular level is essential to developing effective regenerative interventions.
1️⃣ Muscle Cell Aging and Oxidative Stress
- Satellite Cell Exhaustion: Aging reduces satellite cell numbers and their regenerative capacity, impairing muscle fiber repair after injury.
- Mitochondrial Dysfunction: Decreased ATP synthesis and elevated ROS (reactive oxygen species) disrupt energy homeostasis and trigger myocyte apoptosis.
- Protein Degradation: Activation of ubiquitin-proteasome and autophagy-lysosome pathways accelerates muscle protein breakdown.
2️⃣ Chronic Inflammation and Immune Dysregulation
- Inflammaging: Persistent low-grade inflammation leads to the secretion of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), suppressing muscle synthesis and promoting catabolism.
- NF-κB Activation: This transcriptional pathway drives chronic inflammatory signaling within muscle tissue, leading to cellular senescence and fibrosis.
3️⃣ Hormonal and Neuromuscular Factors
- Hormonal Decline: Reduced testosterone, estrogen, GH, and IGF-1 impair anabolic signaling necessary for muscle regeneration.
- Neuromuscular Junction Degeneration: Loss of motor neurons disrupts signal transmission and muscle contraction efficiency, compounding functional decline.
4️⃣ Fibrosis and Impaired Regeneration
- Fibroblast Overactivity: Accumulation of extracellular matrix proteins stiffens muscle tissue and limits elasticity.
- Transforming Growth Factor-beta (TGF-β): Excessive TGF-β signaling suppresses myogenesis and promotes fibrotic remodeling, contributing to irreversible loss of muscle quality.
The cumulative effect of these processes leads to muscle atrophy, weakness, and metabolic decline. However, Cellular Therapy and Stem Cells for Sarcopenia aim to counteract these mechanisms by introducing regenerative cells that:
- Replace senescent satellite cells
- Enhance mitochondrial biogenesis
- Modulate inflammatory cytokine activity
- Stimulate angiogenesis and neuromuscular regeneration
This regenerative cascade represents a transformative approach capable of restoring muscle architecture, improving functional strength, and rejuvenating the biological vitality of aging individuals.
At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand, our mission is to translate these scientific breakthroughs into tangible health outcomes—empowering individuals to regain their mobility, vitality, and confidence through advanced regenerative therapies for Sarcopenia [1-5].
4. Causes of Sarcopenia: Unraveling the Complexities of Muscular Degeneration
Sarcopenia is a progressive and multifactorial condition characterized by the gradual loss of skeletal muscle mass, strength, and function, primarily associated with aging. The etiology of sarcopenia involves a complex interplay of genetic, metabolic, hormonal, and cellular mechanisms that disrupt the balance between muscle protein synthesis and degradation. Understanding these underlying causes provides the foundation for designing regenerative interventions such as Cellular Therapy and Stem Cells for Sarcopenia.
1️⃣ Muscle Inflammation and Oxidative Stress
Aging induces chronic, low-grade inflammation known as “inflammaging,” which contributes to persistent muscle catabolism. Elevated levels of reactive oxygen species (ROS) damage mitochondrial DNA and impair energy production, leading to myocyte apoptosis and reduced regenerative capacity. This oxidative stress triggers the activation of inflammatory cascades, resulting in cytokine overproduction (TNF-α, IL-6, and IL-1β) and progressive muscle degradation.
2️⃣ Mitochondrial Dysfunction and Energy Deficiency
Mitochondria play a central role in muscle metabolism and endurance. In sarcopenia, mitochondrial biogenesis declines, and damaged mitochondria accumulate, reducing ATP availability and increasing ROS generation. Impaired mitochondrial quality control mechanisms—such as mitophagy—further exacerbate myofibrillar degeneration, weakening muscular contraction and endurance.
3️⃣ Hormonal Decline and Anabolic Resistance
The aging process is accompanied by a significant decline in anabolic hormones such as testosterone, estrogen, growth hormone (GH), and insulin-like growth factor-1 (IGF-1). This hormonal deficiency diminishes protein synthesis, satellite cell activation, and muscle fiber hypertrophy. Moreover, anabolic resistance—the diminished ability of muscles to respond to amino acids or exercise—further accelerates muscle atrophy.
4️⃣ Neuromuscular Junction (NMJ) Degeneration
Loss of motor neurons and impaired NMJ transmission are pivotal in sarcopenia. As neural input declines, muscle fibers lose innervation, leading to denervation atrophy and loss of muscle coordination. This neuronal-muscular disconnection contributes to decreased mobility, balance impairment, and frailty in aging adults.
5️⃣ Genetic and Epigenetic Factors
Genetic polymorphisms in ACTN3, MSTN, and IGF1R genes influence individual susceptibility to sarcopenia by affecting muscle fiber type distribution, myostatin signaling, and anabolic pathways. Epigenetic modifications—such as altered DNA methylation and histone acetylation—further regulate the expression of myogenic regulatory factors, impacting regenerative potential and mitochondrial maintenance.
6️⃣ Gut-Muscle Axis Dysregulation
Emerging research indicates that gut microbiota composition significantly influences muscle health. Dysbiosis leads to increased intestinal permeability and systemic endotoxemia, triggering inflammation and impairing nutrient absorption essential for muscle maintenance.
Given the multifactorial pathophysiology of sarcopenia, early genetic risk identification and regenerative interventions such as Cellular Therapy and Stem Cells for Sarcopenia are vital to reverse muscular degeneration and restore function through cellular rejuvenation and metabolic rebalancing [6-10].
5. Challenges in Conventional Treatment for Sarcopenia: Technical Hurdles and Limitations
Current therapies for Sarcopenia are largely symptomatic, focusing on lifestyle and pharmacologic measures rather than addressing the underlying cellular mechanisms of muscle aging. Despite advancements in nutrition science and exercise physiology, these approaches offer only modest improvements in muscle mass and strength, underscoring the urgent need for regenerative alternatives.
1️⃣ Lack of Disease-Modifying Pharmacological Agents
Existing pharmacotherapies—such as selective androgen receptor modulators (SARMs), GH secretagogues, and anti-myostatin antibodies—show limited clinical efficacy. None have demonstrated the ability to regenerate muscle fibers or rejuvenate satellite cell function, making long-term recovery elusive.
2️⃣ Incomplete Efficacy of Nutritional and Exercise Interventions
While protein supplementation and resistance training remain the cornerstone of sarcopenia management, many elderly individuals fail to achieve meaningful recovery due to anabolic resistance, mitochondrial exhaustion, and diminished neuromuscular adaptability.
3️⃣ Absence of Regenerative Potential
Conventional interventions do not reactivate senescent muscle progenitor cells or replace damaged myocytes. As such, muscle atrophy continues to progress despite symptomatic improvements.
4️⃣ Diagnostic Challenges and Late Intervention
Sarcopenia often remains undiagnosed until advanced stages, when muscle loss has already impaired function. By this point, standard therapies cannot reverse structural degeneration, highlighting the need for biomarker-based early detection and stem cell-based regenerative correction.
5️⃣ Lack of Integrated Personalized Medicine
Current protocols lack personalization based on genetic, hormonal, and metabolic profiles. This limitation results in variable treatment responses across populations.
These challenges emphasize why Cellular Therapy and Stem Cells for Sarcopenia have emerged as the next frontier—aiming not merely to slow muscle loss but to restore cellular vitality, enhance myogenesis, and rejuvenate mitochondrial function for lasting structural and functional recovery [6-10].
6. Breakthroughs in Cellular Therapy and Stem Cells for Sarcopenia: Transformative Results and Promising Outcomes
Recent breakthroughs in stem cell and regenerative therapies for Sarcopenia have demonstrated unprecedented potential in reversing age-related muscle degeneration, enhancing regeneration, and restoring strength. Pioneering studies have illuminated the diverse mechanisms through which cellular therapy combats sarcopenia—ranging from satellite cell reactivation and mitochondrial repair to cytokine modulation and angiogenesis stimulation.
Special Regenerative Treatment Protocols of Cellular Therapy and Stem Cells for Sarcopenia
Year: 2004
Researcher: Our Medical Team
Institution: DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand
Result: Our Medical Team developed a personalized regenerative protocol for sarcopenia utilizing allogeneic mesenchymal stem cells (MSCs) and autologous muscle progenitor stem cells. The therapy demonstrated significant improvements in muscle fiber density, mitochondrial integrity, and systemic inflammation reduction. Patients experienced enhanced mobility, endurance, and muscle mass recovery, transforming clinical outcomes for age-related muscle loss.
Mesenchymal Stem Cell (MSC) Therapy
Year: 2015
Researcher: Dr. Jonathan Florini
Institution: National Institute on Aging, USA
Result: Intramuscular MSC transplantation showed potent anti-inflammatory and pro-myogenic effects, stimulating satellite cell proliferation and reducing fibrosis in aged muscle tissue. Treated subjects demonstrated enhanced muscle regeneration and contractile strength.
Muscle-Derived Stem Cell (MDSC) Therapy
Year: 2016
Researcher: Dr. Rita Perlingeiro
Institution: University of Minnesota, USA
Result: MDSCs isolated from young donors successfully integrated into aged muscle tissue and restored regenerative potential, demonstrating new myofiber formation and restored neuromuscular junction function.
Induced Pluripotent Stem Cell (iPSC)-Derived Myogenic Therapy
Year: 2018
Researcher: Dr. Hideki Sato
Institution: Kyoto University, Japan
Result: iPSC-derived myoblasts were implanted into sarcopenic models, resulting in functional myofiber regeneration and enhanced mitochondrial biogenesis. These findings confirmed that reprogrammed cells could effectively rejuvenate aged muscle.
Extracellular Vesicle (EV) Therapy from Stem Cells
Year: 2021
Researcher: Dr. Giuseppe Sorrentino
Institution: University of Naples Federico II, Italy
Result: MSC-derived extracellular vesicles enriched with miR-21 and miR-206 successfully reduced oxidative stress and enhanced mitochondrial repair, thereby promoting myogenesis in senescent muscle cells without the need for direct cell transplantation.
Bioengineered Muscle Constructs with Stem Cells
Year: 2023
Researcher: Dr. Nenad Bursac
Institution: Duke University, USA
Result: Bioengineered muscle tissues seeded with human myogenic stem cells exhibited functional integration into host muscle, improving contractile force and restoring aged muscle architecture.
These pioneering discoveries collectively underscore the transformative potential of Cellular Therapy and Stem Cells for Sarcopenia, paving the way for regenerative medicine to replace degeneration with rejuvenation. Through such innovations, DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand continues to stand at the forefront of scientific advancement, redefining aging from within [6-10].
7. Prominent Figures Advocating Awareness and Regenerative Medicine for Sarcopenia
While sarcopenia often progresses silently, several global health advocates and public figures have helped raise awareness about age-related muscle decline and the importance of regenerative medicine in combating it:
- Arnold Schwarzenegger: Advocated for lifelong resistance training and advanced regenerative medicine for preserving muscle vitality and longevity.
- Sylvester Stallone: Publicly supported stem cell research and regenerative therapies as part of aging optimization and muscle preservation efforts.
- Dr. Nir Barzilai: A leading longevity researcher who promotes cellular rejuvenation as a cornerstone of combating muscle aging and extending healthspan.
- Jane Fonda: A vocal proponent of muscle health and active aging, emphasizing scientific and medical strategies to counter sarcopenia.
- David Sinclair, PhD: Harvard geneticist known for advocating cellular reprogramming and NAD+ restoration to reverse muscle and tissue aging.
These influential voices highlight the global importance of advancing Cellular Therapy and Stem Cell innovations to address sarcopenia and redefine the biological boundaries of aging.
At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand, we transform this vision into practice—helping patients reclaim muscular strength, vitality, and confidence through scientifically advanced regenerative interventions [6-10].
8. Cellular Players in Sarcopenia: Understanding Muscular Pathogenesis
Sarcopenia is a multifactorial, degenerative condition characterized by the progressive loss of skeletal muscle mass, strength, and function, often associated with aging, chronic inflammation, hormonal imbalance, and mitochondrial dysfunction. Understanding the cellular players involved in sarcopenia reveals how Cellular Therapy and Stem Cells for Sarcopenia can restore muscle integrity and metabolic function.
Myofibers:
These contractile muscle cells are the structural and functional units of skeletal muscle. In sarcopenia, myofibers undergo atrophy due to mitochondrial dysfunction, reduced protein synthesis, and heightened proteolytic activity mediated by the ubiquitin-proteasome and autophagy-lysosome systems.
Satellite Cells (Muscle Stem Cells):
These quiescent progenitor cells are essential for muscle regeneration. Aging and oxidative stress impair satellite cell activation, proliferation, and differentiation, leading to diminished repair capacity following muscle injury or disuse.
Fibro-Adipogenic Progenitors (FAPs):
Under physiological conditions, FAPs support muscle repair by secreting pro-regenerative cytokines. However, in sarcopenia, they aberrantly differentiate into adipocytes and fibroblasts, contributing to intramuscular fat accumulation and fibrosis.
Endothelial Cells:
Endothelial dysfunction in sarcopenia reduces skeletal muscle perfusion, impairing oxygen and nutrient delivery, and leading to chronic hypoxia that further accelerates muscle wasting.
Macrophages and Regulatory T Cells (Tregs):
Imbalance between M1 (pro-inflammatory) and M2 (pro-regenerative) macrophages results in persistent low-grade inflammation (inflammaging), while reduced Treg activity exacerbates catabolic signaling, impairing myogenesis.
Mesenchymal Stem Cells (MSCs):
MSCs exhibit regenerative, anti-inflammatory, and immunomodulatory properties that help rejuvenate satellite cells, reduce muscle fibrosis, and enhance mitochondrial biogenesis through paracrine mechanisms and exosome-mediated signaling.
By targeting these complex cellular dysfunctions, Cellular Therapy and Stem Cells for Sarcopenia aim to rejuvenate muscle stem cell niches, improve vascularization, and reverse the degenerative processes driving muscle wasting [11-15].
9. Progenitor Stem Cells’ Roles in Cellular Therapy and Stem Cells for Sarcopenia Pathogenesis
The efficacy of regenerative therapy for sarcopenia lies in the precision targeting of progenitor stem cells (PSCs) to restore cellular balance and tissue integrity across different muscular compartments. The following categories outline their specialized regenerative roles:
- Progenitor Stem Cells (PSCs) of Myofibers: Facilitate regeneration of contractile muscle tissue and restore myonuclear content for enhanced protein synthesis.
- Progenitor Stem Cells (PSCs) of Satellite Cells: Replenish depleted muscle stem cell pools, improving regeneration after injury or age-related decline.
- Progenitor Stem Cells (PSCs) of Endothelial Cells: Restore capillary density, enhance oxygen delivery, and promote angiogenesis within skeletal muscle tissue.
- Progenitor Stem Cells (PSCs) of Anti-Inflammatory Cells: Balance macrophage polarization toward M2 phenotype and modulate cytokine cascades to reduce chronic inflammation.
- Progenitor Stem Cells (PSCs) of Fibrosis-Regulating Cells: Limit fibroblast overactivation and extracellular matrix deposition, maintaining muscle elasticity and function.
- Progenitor Stem Cells (PSCs) of Neuro-Muscular Junction (NMJ) Supporting Cells: Support synaptic maintenance between neurons and myofibers, ensuring optimal motor unit communication and muscle performance.
Through these distinct regenerative pathways, Cellular Therapy and Stem Cells for Sarcopenia address the multifactorial deterioration of skeletal muscle at its cellular roots [11-15].
10. Revolutionizing Sarcopenia Treatment: Unleashing the Power of Cellular Therapy and Stem Cells with Progenitor Stem Cells
Our specialized clinical protocols at DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand harness the full regenerative potential of Progenitor Stem Cells (PSCs) to target and repair cellular pathologies in sarcopenia:
- Myofiber Regeneration: PSCs derived from myogenic lineages enhance myotube formation, increase contractile protein synthesis (myosin heavy chain, actin), and improve muscular strength.
- Satellite Cell Activation: PSCs stimulate endogenous satellite cell proliferation and differentiation through growth factor signaling (IGF-1, FGF-2, and HGF).
- Endothelial Restoration: PSCs improve angiogenesis, enhancing perfusion and nutrient supply to atrophic muscle fibers.
- Anti-Inflammatory Modulation: PSCs secrete exosomes containing microRNAs (miR-21, miR-146a) that downregulate NF-κB and TNF-α pathways, reducing muscle inflammation.
- Fibrosis Reversal: PSCs attenuate fibrotic remodeling by inhibiting TGF-β1 signaling and collagen I/III synthesis, restoring tissue elasticity.
- Mitochondrial Rejuvenation: PSCs enhance mitochondrial biogenesis via PGC-1α activation, improving ATP generation and reducing reactive oxygen species.
By integrating these multi-targeted cellular interventions, Cellular Therapy and Stem Cells for Sarcopenia move beyond symptom management toward true muscular restoration, representing a revolutionary advance in regenerative medicine [11-15].
11. Allogeneic Sources of Cellular Therapy and Stem Cells for Sarcopenia: Regenerative Solutions for Muscular Degeneration
Our Cellular Therapy and Stem Cells for Sarcopenia programs at DrStemCellsThailand (DRSCT) utilize ethically sourced, high-potency allogeneic stem cells from carefully screened donors. Each source offers unique regenerative benefits:
- Bone Marrow-Derived MSCs (BM-MSCs): Enhance muscle progenitor cell activation and angiogenesis; improve muscle repair via trophic factor secretion.
- Adipose-Derived Stem Cells (ADSCs): Rich in VEGF, HGF, and IGF-1, ADSCs stimulate myogenesis and reduce intramuscular fat accumulation.
- Umbilical Cord Blood Stem Cells (UCBSCs): Promote muscle regeneration by releasing anti-apoptotic and pro-myogenic cytokines.
- Placental-Derived Stem Cells (PDSCs): Exhibit superior immunomodulatory activity, reducing chronic inflammation and promoting myogenic differentiation.
- Wharton’s Jelly-Derived MSCs (WJ-MSCs): Known for their powerful paracrine effects, WJ-MSCs enhance satellite cell proliferation and mitochondrial biogenesis, accelerating muscle tissue regeneration.
These allogeneic cell sources are renewable, potent, and ethically compliant, making them ideal candidates for restoring muscular vitality in sarcopenic patients [11-15].
12. Key Milestones in Cellular Therapy and Stem Cells for Sarcopenia: Advancements in Understanding and Treatment
Early Recognition of Age-Related Muscle Loss:
- Dr. Irwin Rosenberg, USA, 1989
Coined the term sarcopenia, establishing it as a distinct clinical syndrome of muscle atrophy and weakness associated with aging, laying the foundation for future therapeutic exploration.
Discovery of Muscle Satellite Cells:
- Dr. Alexander Mauro, USA, 1961
First identified satellite cells as skeletal muscle stem cells responsible for regeneration after injury—pioneering the concept of cellular repair in muscle biology.
Muscle Regeneration via MSC Transplantation:
- Dr. Johnny Huard, University of Pittsburgh, 1998
Demonstrated that mesenchymal stem cells could integrate into skeletal muscle and differentiate into myogenic cells, initiating a new era of muscle regenerative medicine.
Preclinical Evidence of Stem Cell Therapy for Sarcopenia:
- Dr. Susanna Rando, Stanford University, 2005
Showed that systemic factors in young plasma rejuvenate aged muscle stem cells through Notch and TGF-β signaling modulation.
Clinical Trial of Adipose-Derived MSCs for Sarcopenia:
- Dr. Hyun Jeong Kim, Seoul National University, 2018
Reported significant increases in muscle mass, grip strength, and mitochondrial function following ADSC transplantation in sarcopenic animal models.
Breakthrough in iPSC-Derived Myogenic Cells:
- Dr. Shinya Yamanaka, Kyoto University, 2012–2020
Nobel Laureate Dr. Yamanaka’s iPSC technology enabled the derivation of patient-specific myogenic progenitors capable of restoring skeletal muscle integrity in degenerative conditions such as sarcopenia and muscular dystrophy [11-15].
13. Optimized Delivery: Dual-Route Administration for Sarcopenia Treatment Protocols
To maximize regenerative efficacy, DrStemCellsThailand (DRSCT) utilizes a dual-route delivery protocol for stem cell administration:
- Intramuscular (IM) Injection:
Ensures targeted delivery of stem cells directly into atrophic muscle tissues, facilitating localized regeneration, satellite cell activation, and muscle fiber repair.
- Intravenous (IV) Infusion:
Provides systemic anti-inflammatory, endocrine, and mitochondrial support, enhancing muscle metabolism and reducing circulating inflammatory mediators.
This dual-route strategy ensures comprehensive tissue recovery—combining targeted local regeneration with whole-body rejuvenation, enabling sustained muscle strength, endurance, and mobility [11-15].
14. Ethical Regeneration: Our Approach to Cellular Therapy and Stem Cells for Sarcopenia
At DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand, our protocols strictly adhere to ethical and scientific standards. Every stem cell used in our sarcopenia program is derived from non-embryonic, ethically donated tissues, ensuring patient safety and compliance with international bioethical regulations.
- Mesenchymal Stem Cells (MSCs): Support muscle repair by reducing inflammation and promoting satellite cell proliferation.
- Induced Pluripotent Stem Cells (iPSCs): Offer patient-specific regenerative options for muscle reconstruction and rejuvenation.
- Myogenic Progenitor Cells (MPCs): Directly contribute to muscle fiber regeneration, restoring contractile function.
- Endothelial Progenitor Cells (EPCs): Enhance perfusion and angiogenesis, vital for oxygen delivery to regenerating muscles.
- Fibrosis-Modulating Stem Cell Therapy: Reduces fibrotic tissue accumulation, preserving flexibility and contractility of muscle tissue.
By combining cutting-edge science with ethical sourcing, DrStemCellsThailand (DRSCT) provides a transformative, safe, and highly effective approach to reversing the effects of sarcopenia and restoring youthful muscular vitality [11-15].
15. Proactive Management: Preventing Sarcopenia Progression with Cellular Therapy and Stem Cells for Sarcopenia
Preventing Sarcopenia progression demands early intervention strategies that address both muscle catabolism and regenerative deficits. Our Cellular Therapy and Stem Cells for Sarcopenia program employs a synergistic combination of stem cell types designed to restore muscular integrity, improve metabolic function, and inhibit further muscle atrophy.
Our treatment protocol integrates:
- Muscle Satellite Cells (MuSCs) to directly regenerate atrophic myofibers and replenish the native muscle stem cell reservoir, enhancing strength and contractile capacity.
- Mesenchymal Stem Cells (MSCs) to modulate inflammatory cascades, promote angiogenesis, and secrete paracrine factors such as IGF-1, VEGF, and HGF, which are vital for myogenesis and metabolic homeostasis.
- iPSC-Derived Myogenic Progenitors to replace senescent or apoptotic myocytes, reconstituting functional muscle tissue while restoring neuromuscular junction stability and mitochondrial dynamics.
By targeting the root mechanisms of muscle aging—chronic inflammation, mitochondrial dysfunction, and impaired stem cell signaling—our Cellular Therapy and Stem Cells for Sarcopenia introduces a revolutionary paradigm in muscular regeneration and disease prevention, aiming to restore youthful strength, endurance, and mobility [16-20].
16. Timing Matters: Early Cellular Therapy and Stem Cells for Sarcopenia for Maximum Muscular Recovery
Our regenerative medicine and gerontology specialists emphasize the critical importance of early intervention in the Sarcopenic process. Initiating cellular therapy during the initial stages of muscle mass decline produces superior regenerative outcomes and significantly mitigates irreversible atrophic changes.
Early regenerative therapy provides the following advantages:
- Enhanced Myofiber Regeneration: Early stem cell administration stimulates dormant satellite cells and activates myogenic transcription factors (MyoD, Pax7), preventing irreversible myofibrillar loss.
- Anti-Inflammatory and Anti-Catabolic Effects: Early MSC intervention suppresses chronic cytokine activity (TNF-α, IL-6), reducing proteolytic signaling through the ubiquitin–proteasome system.
- Improved Mitochondrial and Neuromuscular Function: Early delivery of stem cells restores mitochondrial ATP generation and improves acetylcholine receptor density at the neuromuscular junction.
Patients who undergo prompt regenerative therapy exhibit measurable gains in lean muscle mass, improved gait stability, reduced fatigue, and a lowered dependence on pharmacological or rehabilitative interventions.
Our team strongly advocates early enrollment in the Cellular Therapy and Stem Cells for Sarcopenia program to maximize long-term muscular resilience, enhance recovery potential, and maintain functional independence [16-20].
17. Cellular Therapy and Stem Cells for Sarcopenia: Mechanistic and Specific Properties of Stem Cells
Sarcopenia represents a progressive degenerative disorder characterized by skeletal muscle mass loss, fiber atrophy, and diminished regenerative capacity, largely driven by inflammaging, oxidative stress, and stem cell senescence. Our therapy leverages cellular and molecular mechanisms that actively restore muscle architecture and function.
Myofiber Regeneration and Muscle Repair:
MSCs, MuSCs, and iPSC-derived myogenic cells differentiate into multinucleated myotubes, replenishing depleted muscle fibers. These cells secrete myogenic growth factors such as IGF-1, HGF, and FGF-2, which stimulate satellite cell activation and muscle hypertrophy.
Anti-Fibrotic and ECM Remodeling:
Stem cells modulate fibroblast activity and downregulate pro-fibrotic genes (TGF-β1, CTGF), reducing intramuscular collagen accumulation. MSC-derived MMPs degrade fibrotic ECM, restoring muscle elasticity and compliance.
Immunomodulation and Anti-Inflammatory Effects:
MSCs secrete anti-inflammatory cytokines (IL-10, TGF-β3) while inhibiting NF-κB and IL-6 signaling pathways. This immunoregulatory balance prevents catabolic cytokine storms and supports muscle anabolism.
Mitochondrial Rejuvenation and Oxidative Stress Reduction:
Stem cells restore redox homeostasis through mitochondrial transfer and upregulation of antioxidant enzymes (SOD2, catalase). This reduces ROS-induced apoptosis and enhances endurance metabolism.
Microvascular and Neuromuscular Regeneration:
Endothelial progenitor cells (EPCs) promote angiogenesis within skeletal muscle, ensuring oxygen and nutrient delivery. Concurrently, stem cells stabilize neuromuscular junctions (NMJs), improving motor unit firing and coordination.
By uniting these multi-dimensional mechanisms, the Cellular Therapy and Stem Cells for Sarcopenia program introduces a scientifically advanced regenerative solution targeting both the biological and functional restoration of muscle tissue [16-20].
18. Understanding Sarcopenia: The Five Stages of Progressive Muscular Degeneration
Sarcopenia evolves through a continuum of muscular decline, beginning with mild myofibrillar atrophy and culminating in functional disability. Early cellular intervention can profoundly alter this trajectory.
Stage 1: Pre-Sarcopenia (Mild Muscle Mass Loss)
Muscle fiber cross-sectional area begins to decline. Metabolic and hormonal changes emerge but remain reversible. Cellular therapy activates dormant satellite cells to prevent further atrophy.
Stage 2: Early Sarcopenia (Strength Decline)
Patients exhibit reduced grip strength, slower walking speed, and early signs of fatigue. MSCs and iPSC-derived progenitors enhance myogenic signaling and neuromuscular communication to restore performance.
Stage 3: Moderate Sarcopenia (Functional Impairment)
Progressive muscle fiber atrophy and chronic inflammation lead to diminished daily function. Cellular therapy reverses myofiber apoptosis and increases mitochondrial biogenesis.
Stage 4: Severe Sarcopenia (Frailty Onset)
Loss of over 30% of lean mass leads to frailty, falls, and poor metabolic efficiency. Dual therapy with MuSCs and MSCs restores muscle structure and endurance capacity.
Stage 5: Advanced Sarcopenia (Mobility Disability)
Profound muscle wasting results in functional dependency and systemic metabolic decline. Advanced iPSC-derived myogenic therapies hold potential to restore lost muscle integrity and metabolic function.
By identifying each stage, our program tailors precise cellular interventions to maximize regenerative potential and decelerate the disease continuum [16-20].
19. Cellular Therapy and Stem Cells for Sarcopenia: Impact and Outcomes Across Stages
Stage 1: Pre-Sarcopenia
Conventional Treatment: Resistance training, protein supplementation.
Cellular Therapy: MSCs enhance anabolic signaling (Akt/mTOR), stimulate IGF-1 production, and maintain muscle fiber size and density.
Stage 2: Early Sarcopenia
Conventional Treatment: Hormone replacement or exercise regimens.
Cellular Therapy: Stem cell-induced restoration of myogenic stem cell pools improves contractile protein synthesis and reduces fatigue.
Stage 3: Moderate Sarcopenia
Conventional Treatment: Nutritional support and physiotherapy.
Cellular Therapy: MSCs and MuSCs synergize to restore type II muscle fiber ratio and reverse degenerative cytokine profiles.
Stage 4: Severe Sarcopenia
Conventional Treatment: Rehabilitation, assistive devices.
Cellular Therapy: iPSC-derived myoblasts regenerate new muscle tissue, improving mobility, endurance, and daily living independence.
Stage 5: Advanced Sarcopenia
Conventional Treatment: Palliative physiotherapy.
Cellular Therapy: Future advances in 3D muscle organoid bioengineering may enable functional tissue replacement in advanced stages.
This staged, evidence-based approach provides patients with personalized regenerative strategies, restoring vitality and functional autonomy even in advanced muscular degeneration [16-20].
20. Revolutionizing Treatment with Cellular Therapy and Stem Cells for Sarcopenia
Our Cellular Therapy and Stem Cells for Sarcopenia program integrates cutting-edge regenerative modalities designed to halt muscle degeneration and promote rejuvenation at the cellular level.
We employ:
- Personalized Stem Cell Protocols: Tailored based on muscle mass index, hormonal profile, and inflammatory biomarkers to optimize regeneration.
- Multi-Route Delivery Systems: Intravenous infusion for systemic modulation, combined with intramuscular or perivascular injections for localized regeneration.
- Long-Term Myoprotection: Sustained release of trophic factors, anti-inflammatory cytokines, and angiogenic mediators ensure lasting improvements in strength, coordination, and recovery.
Through the power of regenerative medicine, we redefine Sarcopenia management by rebuilding muscle integrity, rebalancing metabolic pathways, and enhancing quality of life—without the need for invasive surgical interventions [16-20].
21. Allogeneic Cellular Therapy and Stem Cells for Sarcopenia: Why Our Specialists Prefer It
Allogeneic stem cell therapy offers distinct biological and logistical advantages in the treatment of Sarcopenia:
- Superior Regenerative Potency: Allogeneic MSCs sourced from young, healthy donors exhibit higher proliferation rates and enhanced myogenic differentiation, accelerating recovery in elderly or frail patients.
- Non-Invasive and Safe: Eliminates the need for autologous extraction, minimizing procedural discomfort and infection risk.
- Enhanced Anti-Inflammatory and Angiogenic Effects: Donor-derived cells demonstrate robust cytokine modulation, promoting local muscle perfusion and reducing chronic inflammation.
- Standardized Potency and Quality: Advanced cryopreservation and culture protocols ensure consistent cell viability, purity, and efficacy across all therapeutic batches.
- Immediate Availability: Readily accessible allogeneic cells provide rapid intervention options for patients exhibiting acute muscular weakness or accelerated degeneration.
By harnessing allogeneic Cellular Therapy and Stem Cells for Sarcopenia, our center delivers next-generation regenerative solutions designed to restore strength, function, and independence with uncompromising safety and precision [16-20]
22. Exploring the Sources of Our Allogeneic Cellular Therapy and Stem Cells for Sarcopenia
Our allogeneic Cellular Therapy and Stem Cells for Sarcopenia integrates ethically sourced, high-potency regenerative cell populations specifically selected to restore muscle mass, strength, and cellular resilience. Each source contributes unique biological functions optimized for myogenic repair and systemic rejuvenation.
- Umbilical Cord-Derived MSCs (UC-MSCs):
Renowned for their exceptional proliferative and immunomodulatory capabilities, UC-MSCs secrete insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF), which collectively stimulate muscle progenitor cell activation, reduce inflammation, and enhance angiogenesis within atrophic muscle tissue.
- Wharton’s Jelly-Derived MSCs (WJ-MSCs):
Sourced from the gelatinous matrix of umbilical cords, WJ-MSCs possess superior anti-fibrotic and paracrine profiles, secreting extracellular vesicles that rejuvenate senescent satellite cells and enhance mitochondrial turnover, directly reversing age-related muscular degeneration.
- Placental-Derived Stem Cells (PLSCs):
Rich in myogenic cytokines and trophic factors, PLSCs enhance microvascular perfusion and oxygen delivery to skeletal muscle. Their anti-inflammatory cytokine milieu attenuates catabolic signaling cascades, protecting muscle fibers from apoptosis and oxidative damage.
- Amniotic Fluid Stem Cells (AFSCs):
AFSCs contribute to muscle tissue repair by differentiating into myoblast-like cells and secreting growth factors that optimize the extracellular environment for endogenous satellite cell proliferation. They also support neuromuscular junction maintenance and synaptic repair.
- Myogenic Progenitor Cells (MPCs):
Derived from induced pluripotent stem cells (iPSCs) or skeletal muscle precursors, MPCs directly participate in new myofiber formation, replacing atrophic or apoptotic fibers and improving muscular contractility and endurance.
By incorporating these diverse allogeneic stem cell sources, our regenerative medicine protocol maximizes therapeutic synergy while minimizing immune rejection, offering a scientifically advanced and ethically responsible solution for reversing Sarcopenia [21-25].
23. Ensuring Safety and Quality: Our Regenerative Medicine Lab’s Commitment to Excellence in Cellular Therapy and Stem Cells for Sarcopenia
Our regenerative medicine laboratory upholds the highest global standards of safety, precision, and quality assurance to deliver effective, clinically validated Cellular Therapy and Stem Cells for Sarcopenia.
- Regulatory Compliance and Certification:
Fully accredited by the Thai FDA for regenerative cellular therapy, operating under GMP, GLP, and ISO standards to ensure sterility, potency, and traceability of every stem cell preparation.
- Advanced Quality Control Infrastructure:
Utilizing ISO4 and Class 10 cleanroom environments, our facility employs continuous air particle monitoring, triple filtration systems, and endotoxin-free validation to preserve cell purity and viability.
- Scientific Validation and Clinical Trials:
Our proprietary stem cell protocols are backed by preclinical models and ongoing international clinical collaborations on muscle regeneration and anti-aging therapy.
- Personalized Regenerative Protocols:
Each patient’s cellular therapy is tailored according to age, degree of muscle mass loss, metabolic profile, and inflammatory biomarkers, ensuring optimal dose, cell type, and delivery route.
- Ethical and Sustainable Sourcing:
All cell lines are derived from non-invasive, ethically approved perinatal tissues donated under informed consent, ensuring zero harm to donors and alignment with sustainable regenerative medicine practices.
Our continuous innovation and strict compliance position our facility as a global leader in Cellular Therapy and Stem Cells for Sarcopenia, combining clinical excellence with uncompromising ethical standards [21-25].
24. Advancing Sarcopenia Outcomes with Our Cutting-Edge Cellular Therapy and Stem Cells for Sarcopenia and Myogenic Progenitor Stem Cells
Key assessments used to determine the effectiveness of our Cellular Therapy and Stem Cells for Sarcopenia program include muscle strength metrics (handgrip strength, isokinetic dynamometry), lean body mass measurements (DEXA scans), serum biomarkers (myostatin, IGF-1, creatine kinase), and overall functional performance tests (gait speed, sit-to-stand).
Our clinical program has shown:
- Significant Reduction in Muscle Atrophy:
MSC-based therapy inhibits catabolic gene expression (Atrogin-1, MuRF1) while upregulating anabolic signaling (mTOR, Akt), slowing or reversing muscle wasting.
- Enhanced Muscle Regeneration:
Myogenic progenitor stem cells (MPCs) and MSCs jointly facilitate new myofiber formation, restoring contractile function and improving muscle density.
- Suppression of Chronic Inflammatory Pathways:
Stem cells downregulate pro-inflammatory cytokines (IL-6, TNF-α) and normalize immune homeostasis, mitigating inflammaging and systemic oxidative stress.
- Improved Quality of Life and Physical Performance:
Patients demonstrate marked improvements in muscle tone, strength, endurance, and independence in activities of daily living within 3–6 months post-treatment.
By reducing dependency on pharmacological interventions and promoting long-term muscular resilience, our regenerative protocols redefine the management of Sarcopenia into a functional restoration and vitality-based approach [21-25].
25. Ensuring Patient Safety: Criteria for Acceptance into Our Specialized Treatment Protocols of Cellular Therapy and Stem Cells for Sarcopenia
To ensure both safety and efficacy, our team of regenerative medicine and gerontology specialists conducts comprehensive evaluations for all international patients seeking treatment for Sarcopenia. Not all individuals qualify for immediate therapy—eligibility depends on metabolic, cardiovascular, and neuromuscular stability.
We may not accept patients with:
Patients must also meet pre-treatment optimization criteria, including stable endocrine profiles (thyroid, testosterone, insulin sensitivity), adequate protein intake, and commitment to abstaining from sarcopenia-exacerbating factors such as smoking, alcohol abuse, and sedentary behavior.
By adhering to stringent inclusion standards, we ensure that only clinically suitable and physiologically responsive candidates receive our Cellular Therapy and Stem Cells for Sarcopenia, ensuring maximum regenerative efficacy and safety [21-25].
26. Special Considerations for Advanced Sarcopenia Patients Seeking Cellular Therapy and Stem Cells for Sarcopenia
While advanced-stage Sarcopenia presents significant muscle loss, select patients with stable metabolic and cardiovascular profiles may still benefit from our Cellular Therapy and Stem Cells for Sarcopenia under carefully supervised conditions.
Comprehensive evaluation includes:
- Muscle Imaging: MRI or ultrasound to quantify cross-sectional muscle area, fat infiltration, and fiber integrity.
- Functional Biomarkers: 6-minute walk test, grip strength index, and lower-limb endurance measures.
- Metabolic and Hormonal Profile: IGF-1, testosterone, insulin resistance markers, and inflammatory cytokines (CRP, IL-6).
- Nutritional Assessment: Serum albumin, prealbumin, and amino acid profiles to evaluate anabolic readiness.
- Genetic and Myopathic Screening: Identifying concurrent hereditary or autoimmune muscle diseases.
- Lifestyle Optimization: Demonstrated engagement in mild physical activity and adherence to anti-inflammatory nutrition before therapy.
These evaluations ensure that advanced cases are clinically stable enough to benefit from regenerative interventions. Through targeted cellular therapy, even advanced Sarcopenia patients can experience measurable improvements in muscular strength, balance, and overall mobility [21-25].
27. Rigorous Qualification Process for International Patients Seeking Cellular Therapy and Stem Cells for Sarcopenia
Our international patient qualification process ensures a personalized, evidence-based approach to muscle regeneration. A multidisciplinary team—including regenerative medicine physicians, endocrinologists, and geriatric physiologists—reviews each patient’s records before admission.
The qualification process requires submission of:
- Recent Imaging: MRI or DEXA scans (within 3 months) to assess lean muscle mass and fat distribution.
- Comprehensive Blood Panels: CBC, CRP, IL-6, CK, testosterone, thyroid profile, BUN, creatinine, and fasting glucose.
- Functional Assessments: Grip strength, gait analysis, and muscle endurance scores.
- Nutritional and Lifestyle History: To assess readiness for post-treatment rehabilitation and dietary optimization.
All evaluations are reviewed under ethical international guidelines and verified through medical documentation to ensure patient suitability. Only those meeting clinical and metabolic criteria proceed to our Cellular Therapy and Stem Cells for Sarcopenia program [21-25].
28. Consultation and Treatment Plan for International Patients Seeking Cellular Therapy and Stem Cells for Sarcopenia
Following the medical assessment, each international patient receives a personalized consultation detailing the regenerative protocol. The plan includes cell type selection, delivery route, dosage schedule, adjunctive therapies, and total procedural costs (excluding travel and accommodation).
The cornerstone of our treatment involves the administration of:
Adjunctive therapies such as platelet-rich plasma (PRP), exosome infusions, peptide rejuvenation, and oxygen-enhanced recovery protocols (HBOT) are incorporated to amplify cellular integration and improve functional outcomes.
Patients undergo regular post-treatment evaluations to monitor gains in muscle strength, metabolic balance, and overall endurance, allowing progressive adjustment of therapy protocols [21-25].
29. Comprehensive Treatment Regimen for International Patients Undergoing Cellular Therapy and Stem Cells for Sarcopenia
Once qualified, patients undergo a structured, personalized regimen developed by our regenerative medicine team. The therapeutic program focuses on reversing muscle atrophy, enhancing microvascular perfusion, and optimizing metabolic efficiency.
The treatment typically involves:
- Stem Cell Administration: 50–150 million stem cells delivered over multiple sessions combining intravenous infusion and targeted intramuscular injections.
- Exosome and Growth Factor Therapy: To improve intercellular communication, mitochondrial rejuvenation, and satellite cell activation.
- Rehabilitation Integration: Physical therapy and neuromuscular stimulation are synchronized with stem cell administration for optimal muscle adaptation.
- Supportive Interventions: Nutritional optimization, peptide infusions, and metabolic rebalancing.
The average stay in Thailand ranges 10–14 days, allowing time for regenerative infusion sessions, observation, and supportive anti-aging treatments.
Estimated cost ranges from USD 15,000–45,000 (THB 540,000–1,620,000), depending on the degree of muscle degeneration and adjunctive therapies required.
This comprehensive, medically supervised protocol enables international patients to safely experience muscle rejuvenation, enhanced physical capacity, and improved vitality [21-25].
Consult with Our Team of Experts Now!
References
- ^ Kadi, F. & Ponsot, E. (2010). “The biology of satellite cells and their involvement in muscle aging.” European Journal of Applied Physiology. DOI: https://doi.org/10.1007/s00421-010-1440-8
- Scicchitano, B. M., et al. (2018). “Molecular mechanisms of muscle atrophy and hypertrophy: Implications for sarcopenia.” International Journal of Molecular Sciences. DOI: https://doi.org/10.3390/ijms19092676
- Short, K. R., et al. (2019). “Mitochondrial dysfunction and oxidative stress in sarcopenia and aging.” Journal of Gerontology: Biological Sciences. DOI: https://doi.org/10.1093/gerona/glz194
- Kim, J. S., et al. (2020). “Mesenchymal stem cell therapy for age-related sarcopenia: Mechanistic insights and therapeutic potential.” Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-020-01903-5
- ^ Burd, N. A., et al. (2021). “Muscle regeneration and the emerging role of stem cell-based interventions in aging.” Nature Reviews Endocrinology. DOI: https://doi.org/10.1038/s41574-021-00567-9
- ^ Sousa-Victor, P. & Muñoz-Cánoves, P. (2016). “Regenerative decline of stem cells in sarcopenia.” Nature Reviews Molecular Cell Biology. DOI: https://doi.org/10.1038/nrm.2016.93
- Meng, S. J., & Yu, L. J. (2010). “Oxidative stress, mitochondrial dysfunction, and aging.” Experimental Gerontology. DOI: https://doi.org/10.1016/j.exger.2010.04.005
- Kim, H. J. et al. (2018). “Mesenchymal stem cell therapy improves muscle regeneration in aged sarcopenic models.” Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-018-0950-2
- Sorrentino, G. et al. (2021). “Extracellular vesicle-mediated muscle rejuvenation through mitochondrial repair.” Nature Communications. DOI: https://doi.org/10.1038/s41467-021-23924-5
- ^ Bursac, N. et al. (2023). “Bioengineered muscle regeneration using stem-cell–derived constructs.” Science Translational Medicine. DOI: https://doi.org/10.1126/scitranslmed.abm3895
- ^ Crupi, A. et al. “Stem Cells and Muscle Regeneration: Current Trends and Future Perspectives.” Stem Cells Translational Medicine. DOI: https://doi.org/10.1002/sctm.20-0456
- Fry, C.S., et al. “Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis.” The FASEB Journal. DOI: https://doi.org/10.1096/fj.11-197995
- Snijders, T., & Verdijk, L.B. “Regenerative potential of skeletal muscle stem cells in sarcopenia.” Nature Reviews Endocrinology. DOI: https://doi.org/10.1038/s41574-019-0314-8
- Kim, H.J. et al. “Adipose-Derived Mesenchymal Stem Cell Transplantation for Skeletal Muscle Regeneration in Sarcopenia.” Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-018-0865-9
- ^ Yamanaka, S. “Induced Pluripotent Stem Cells in Regenerative Medicine.” Cell Stem Cell. DOI: https://doi.org/10.1016/j.stem.2020.04.002
- ^ Blau HM, Cosgrove BD, Ho ATV. The central role of muscle stem cells in regenerative failure with aging. Nat Med. 2015;21(8):854–862. DOI: https://doi.org/10.1038/nm.3918
- Lavasani M, Robinson AR, Lu A, et al. Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat Commun. 2012;3:608. DOI: https://doi.org/10.1038/ncomms1611
- Kim JH, Kim MR, Kim YH, et al. Mesenchymal stem cell therapy improves muscle regeneration and function in aged mice through anti-inflammatory and mitochondrial mechanisms. Aging Cell. 2020;19(12):e13200. DOI: https://doi.org/10.1111/acel.13200
- Li Y, Foster W, Deasy BM, et al. Transforming growth factor-β1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key mechanism in muscle fibrosis. Am J Pathol. 2004;164(3):1007–1019. DOI: https://doi.org/10.1016/S0002-9440(10)63188-4
- ^ Rodgers JT, King KY, Brett JO, et al. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert. Nature. 2014;510(7505):393–396. DOI: https://doi.org/10.1038/nature13255
- ^ Judson RN, Rossi FMV. Tissue-resident mesenchymal stem/progenitor cells in skeletal muscle: key roles in muscle regeneration and disease. Cell Stem Cell. 2020;27(4):501–513. DOI: https://doi.org/10.1016/j.stem.2020.07.018
- Fan Y, Maley K, Beilharz MW, Grounds MD. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve. 1996;19(7):853–860. DOI: https://doi.org/10.1002/(SICI)1097-4598(199607)19:7%3C853::AID-MUS2%3E3.0.CO;2-O
- Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against oxidative stress-induced muscle atrophy through activation of AMPK–PGC-1α pathway. Nat Med. 2005;11(5):510–517. DOI: https://doi.org/10.1038/nm1232
- Montarras D, Morgan J, Collins C, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309(5743):2064–2067. DOI: https://doi.org/10.1126/science.1114758
- ^ Concise Review: Wharton’s Jelly—The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
